FYR Bio

FYR Bio is a private, pre-revenue diagnostics company founded in 2020 and based in San Diego. The company has developed the EV-Omics (EVO) platform, which utilizes a proprietary technology called SPARCs to enrich for disease-specific extracellular vesicles from blood samples, followed by AI-enabled analysis of their RNA and protein cargo. This approach aims to overcome the signal-to-noise challenges of liquid biopsies to generate detailed molecular snapshots of disease for applications in biomarker discovery, drug development, and personalized patient care. FYR Bio appears to be in a platform validation and business development stage, seeking partnerships with pharmaceutical and diagnostic companies.

EV-Omics (EVO) platform combining proprietary SPARCs technology for enriching disease-specific extracellular vesicles (EVs) from blood with AI-enabled multi-omic analysis of EV RNA and protein cargo.

FYR Bio competes in the broad liquid biopsy market against companies focused on cell-free DNA (e.g., Guardant Health, GRAIL) and other EV-based approaches (e.g., Exosome Diagnostics, Bio-Techne). Its differentiation lies in the combination of proprietary EV enrichment (SPARCs) and integrated AI-driven multi-omic analysis of proteins and RNA.